COPENHAGEN, MARCH 22, 2016 – AntibioTx detected no systemic availability of ATx201 after the application in Hanford minipigs. The study protocol consisted of applying ATx201 twice a day for 28-days, followed by a 28-day recovery period to ensure no detectable genotoxicity.
The study was conducted by researchers at the In-Life Testing Facility at Sinclair Research Center, LLC – located in Missouri, USA. Sinclair Research is specialized in preclinical studies and has broad experience in applied human and veterinary models.
Dr. Morten Sommer, CSO of AntibioTx, commented: “We are pleased about the outcome of the minipig study which supports further development of ATx201”.
This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.
